Lilly Invests $6 Billion in Alabama Facility for Next-Generation Medicines

Eli Lilly and Company has announced plans to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama, aimed at producing next-generation synthetic medicine active pharmaceutical ingredients (APIs), including small molecule and peptide therapies. The state-of-the-art facility will be among those producing Lilly’s first oral, small molecule GLP-1 receptor agonist, orforglipron, which the company expects to submit to global regulatory agencies for obesity later this year.

The Huntsville site is projected to create 450 high-value jobs, including engineers, scientists, lab technicians, and operations personnel. Construction, scheduled to begin in 2026, is expected to generate approximately 3,000 construction jobs, with full completion anticipated by 2032.

David A. Ricks, Lilly’s chairman and CEO, highlighted Huntsville’s strong foundation in science, innovation, and advanced manufacturing as key reasons for the selection. “Today’s investment continues the onshoring of active pharmaceutical ingredient production, strengthening supply chain resilience and reliable access to medicines for patients in the U.S.,” Ricks said.

Governor Kay Ivey welcomed the announcement, emphasizing the facility as the largest initial investment in Alabama’s history. She noted that for every dollar Lilly invests, up to four dollars in additional local economic activity is expected, with ripple effects in logistics, supply chain, and retail sectors.

The Greenbrier South location was chosen from over 300 applicants due to its proximity to the HudsonAlpha Institute for Biotechnology, workforce training opportunities, and favorable access to utilities and transportation. Lilly plans to integrate advanced technologies, including AI, machine learning, digital monitoring, and data analytics, to optimize manufacturing processes and ensure high-quality, reliable medicine production.

Edgardo Hernandez, Lilly’s executive vice president and president of Manufacturing Operations, emphasized the company’s commitment to environmental stewardship, highlighting efforts to minimize waste and achieve carbon neutrality.

This facility is part of Lilly’s broader U.S. manufacturing expansion, which includes new sites in Texas and Virginia, an expansion in Puerto Rico, and one more location to be announced soon. The initiative underscores Lilly’s strategy to bolster domestic production capabilities and advance the availability of innovative therapies.